Core Viewpoint - Novo Nordisk's top investor, the Novo Nordisk Foundation, is taking control of the board to enhance focus on the U.S. market and revive sales of the weight-loss drug Wegovy, following the resignation of the current chair and six independent board members [1][2][3] Group 1 - The Novo Nordisk Foundation will propose Lars Rebien Sorensen, a former CEO, as the new chair for the next two to three years [2] - The outgoing board was criticized for being slow to adapt to changes in the U.S. market and for being overly cautious regarding management changes [3][5] - The foundation aims to restore sales and investor confidence after a significant drop in share prices, which fell over 40% this year due to increased competition from Eli Lilly [3][5] Group 2 - New CEO Mike Doustdar, who took over in August, is supported by the foundation and is implementing job cuts and a refocus on key markets [4] - The foundation proposed six new board members, all European, with five having extensive experience in pharmaceuticals and related industries [6] - The foundation's actions are part of a broader strategy to address pressures from U.S. drug pricing policies [5][6]